GlassScriptPhysician profile
Oscar Estrada
NPI 1275681173
$1,382.66
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $250 · 2021: $68.73 · 2022: $20.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $776.29 | 2019-2021 | |
| Alkermes, INC. | $238.54 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $141.47 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $105.51 | 2020 | |
| Abbvie INC. | $33.11 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $24.70 | 2019 | |
| Lundbeck LLC | $22.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.65 | 2019 | |
| Adlon Therapeutics L.P. | $12.86 | 2020 | |
| Allergan, INC. | $11.59 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.